Ublituximab is the third anti-CD20 therapy for multiple sclerosis and a worthy rival to Ocrevus and Kesimpta.
multiple sclerosis
Posted inAutoimmune Diseases, Clinical Trials, Neuroscience
Even Severe Multiple Sclerosis Can Be Cured
Atara Biotherapeutics and its awesome T-cell therapy against Epstein–Barr virus can really cure progressive forms of multiple sclerosis.
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Kesimpta: Highly Effective New Drug for Multiple Sclerosis
Ofatumumab by Novartis is as good and convenient as Ocrevus by Roche against multiple sclerosis.
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Ponvory: Another Drug for Multiple Sclerosis
Ponesimod is a new drug that changes the course of multiple sclerosis and is a direct competitor to Gilenya (fingolimod), Mayzent (siponimod), and Zeposia (ozanimod).
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Zeposia: New Drug to Treat Relapsing Multiple Sclerosis
Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Mayzent: New Drug for Treatment of Secondary Progressive Multiple Sclerosis
Siponimod released by Novartis is an improved version of Gilenya.